Cargando…

Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Lung cancer is the second cause of cancer related deaths worldwide. Chemotherapy and immunotherapy represent the current standard of care for advanced NSCLC. Platinum-based chemotherapy expands late-differentiated T cell populations. Therefore, immune restoration after chemotherapy to adjuvate the i...

Descripción completa

Detalles Bibliográficos
Autores principales: Suárez, Gisela María, Catalá, Mauricio, Peña, Yadira, Portela, Susana, Añé-Kourí, Ana Laura, González, Amnely, Lorenzo-Luaces, Patricia, Díaz, Manuel, Molina, María de los A., Pereira, Karla, Hernández, Jenysbel de la C., Ramos, Raúl, Reyes, Mary Carmen, Ledón, Nuris, Mazorra, Zaima, Crombet, Tania, Lage, Agustin, Saavedra, Danay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828575/
https://www.ncbi.nlm.nih.gov/pubmed/35155258
http://dx.doi.org/10.3389/fonc.2022.823287
_version_ 1784647878192398336
author Suárez, Gisela María
Catalá, Mauricio
Peña, Yadira
Portela, Susana
Añé-Kourí, Ana Laura
González, Amnely
Lorenzo-Luaces, Patricia
Díaz, Manuel
Molina, María de los A.
Pereira, Karla
Hernández, Jenysbel de la C.
Ramos, Raúl
Reyes, Mary Carmen
Ledón, Nuris
Mazorra, Zaima
Crombet, Tania
Lage, Agustin
Saavedra, Danay
author_facet Suárez, Gisela María
Catalá, Mauricio
Peña, Yadira
Portela, Susana
Añé-Kourí, Ana Laura
González, Amnely
Lorenzo-Luaces, Patricia
Díaz, Manuel
Molina, María de los A.
Pereira, Karla
Hernández, Jenysbel de la C.
Ramos, Raúl
Reyes, Mary Carmen
Ledón, Nuris
Mazorra, Zaima
Crombet, Tania
Lage, Agustin
Saavedra, Danay
author_sort Suárez, Gisela María
collection PubMed
description Lung cancer is the second cause of cancer related deaths worldwide. Chemotherapy and immunotherapy represent the current standard of care for advanced NSCLC. Platinum-based chemotherapy expands late-differentiated T cell populations. Therefore, immune restoration after chemotherapy to adjuvate the immunotherapeutic potential could be crucial. The aim of this study was to evaluate the effect of Biomodulina T (BT), a thymic polypeptide fraction, on peripheral lymphocytes subpopulations in the context of cancer disease. Additionally, whether these effects might induce a better response to CIMAvax-EGF, an epidermal growth factor (EGF) depleting immunotherapy. Eighteen advanced NSCLC patients were evaluated after being treated with platinum-based chemotherapy. We found that the frequency of terminally differentiated effector T cells re-expressing CD45RA (EMRA) CD4+ (p=0.0031) and CD8+ (p=0.0372) T cells decreased with the administration of BT, whereas CD4+ naive T cells increase in more than 70% of the patients. Remarkably, CD4+ and CD8+ T lymphocytes expressing programmed cell death receptor-1 (PD1) significantly decreased after BT administration (p=0.0005 and p<0.0001, respectively). We also found an enhancement of the anti-EGF antibody response with a large percentage of patients treated with CIMAvax-EGF reaching the good antibody response condition after four vaccine doses. Moreover, the median overall survival of patients treated with CIMAvax-EGF was 16.09 months. In conclusion, our results suggest that the immunorestoration generated by the administration of BT after first-line chemotherapy may induce a better immune response to CIMAvax-EGF that could translate into the clinical benefit of patients diagnosed with advanced NSCLC.
format Online
Article
Text
id pubmed-8828575
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88285752022-02-11 Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy Suárez, Gisela María Catalá, Mauricio Peña, Yadira Portela, Susana Añé-Kourí, Ana Laura González, Amnely Lorenzo-Luaces, Patricia Díaz, Manuel Molina, María de los A. Pereira, Karla Hernández, Jenysbel de la C. Ramos, Raúl Reyes, Mary Carmen Ledón, Nuris Mazorra, Zaima Crombet, Tania Lage, Agustin Saavedra, Danay Front Oncol Oncology Lung cancer is the second cause of cancer related deaths worldwide. Chemotherapy and immunotherapy represent the current standard of care for advanced NSCLC. Platinum-based chemotherapy expands late-differentiated T cell populations. Therefore, immune restoration after chemotherapy to adjuvate the immunotherapeutic potential could be crucial. The aim of this study was to evaluate the effect of Biomodulina T (BT), a thymic polypeptide fraction, on peripheral lymphocytes subpopulations in the context of cancer disease. Additionally, whether these effects might induce a better response to CIMAvax-EGF, an epidermal growth factor (EGF) depleting immunotherapy. Eighteen advanced NSCLC patients were evaluated after being treated with platinum-based chemotherapy. We found that the frequency of terminally differentiated effector T cells re-expressing CD45RA (EMRA) CD4+ (p=0.0031) and CD8+ (p=0.0372) T cells decreased with the administration of BT, whereas CD4+ naive T cells increase in more than 70% of the patients. Remarkably, CD4+ and CD8+ T lymphocytes expressing programmed cell death receptor-1 (PD1) significantly decreased after BT administration (p=0.0005 and p<0.0001, respectively). We also found an enhancement of the anti-EGF antibody response with a large percentage of patients treated with CIMAvax-EGF reaching the good antibody response condition after four vaccine doses. Moreover, the median overall survival of patients treated with CIMAvax-EGF was 16.09 months. In conclusion, our results suggest that the immunorestoration generated by the administration of BT after first-line chemotherapy may induce a better immune response to CIMAvax-EGF that could translate into the clinical benefit of patients diagnosed with advanced NSCLC. Frontiers Media S.A. 2022-01-27 /pmc/articles/PMC8828575/ /pubmed/35155258 http://dx.doi.org/10.3389/fonc.2022.823287 Text en Copyright © 2022 Suárez, Catalá, Peña, Portela, Añé-Kourí, González, Lorenzo-Luaces, Díaz, Molina, Pereira, Hernández, Ramos, Reyes, Ledón, Mazorra, Crombet, Lage and Saavedra https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Suárez, Gisela María
Catalá, Mauricio
Peña, Yadira
Portela, Susana
Añé-Kourí, Ana Laura
González, Amnely
Lorenzo-Luaces, Patricia
Díaz, Manuel
Molina, María de los A.
Pereira, Karla
Hernández, Jenysbel de la C.
Ramos, Raúl
Reyes, Mary Carmen
Ledón, Nuris
Mazorra, Zaima
Crombet, Tania
Lage, Agustin
Saavedra, Danay
Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy
title Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy
title_full Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy
title_fullStr Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy
title_full_unstemmed Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy
title_short Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy
title_sort thymic polypeptide fraction biomodulina t decreases exhausted and terminally differentiated emra t cells in advanced lung cancer patients treated with platinum-based chemotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828575/
https://www.ncbi.nlm.nih.gov/pubmed/35155258
http://dx.doi.org/10.3389/fonc.2022.823287
work_keys_str_mv AT suarezgiselamaria thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT catalamauricio thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT penayadira thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT portelasusana thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT anekourianalaura thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT gonzalezamnely thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT lorenzoluacespatricia thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT diazmanuel thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT molinamariadelosa thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT pereirakarla thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT hernandezjenysbeldelac thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT ramosraul thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT reyesmarycarmen thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT ledonnuris thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT mazorrazaima thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT crombettania thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT lageagustin thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy
AT saavedradanay thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy